Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Elche (61)

2026

  1. Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 19

  2. Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 1, pp. 58-73

  3. Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

    Journal of the International AIDS Society, Vol. 29, Núm. 4

  4. Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real-World Evidence From a Multicentre Spanish Study

    Australasian Journal of Dermatology, Vol. 67, Núm. 1, pp. e40-e44

  5. Influence of the level of education on cognitive function in Parkinson’s disease

    Journal of Neural Transmission, Vol. 133, Núm. 4, pp. 663-681

  6. Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 5, pp. 690-709

  7. Predictive Factors and Impact of Significant Weight Loss on Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice

  8. Prevalence and mortality of tuberculosis at HIV diagnosis in Spain, 2004–2024

    International Journal of Infectious Diseases, Vol. 167

  9. Use of long-acting therapies for the HIV treatment in the Spanish pediatric cohort (CoRISpe)

    Journal of Infection and Public Health, Vol. 19, Núm. 5

2025

  1. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

    Journal of Antimicrobial Chemotherapy, Vol. 80, Núm. 12, pp. 3438-3451

  2. Are children and adolescents living with HIV in Europe and South Africa at higher risk of SARS-CoV-2 and poor COVID-19 outcomes?

    Epidemiology and Infection, Vol. 153

  3. Artificial intelligence for identification of candidates for device-aided therapy in Parkinson's disease: DELIST-PD study

    Computers in Biology and Medicine, Vol. 185

  4. Comparison of clinical measures of motor function with a Holter monitor in Parkinson's disease

    Clinical Parkinsonism and Related Disorders, Vol. 12

  5. Correction to: Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline (Journal of Neurology, (2025), 272, 3, (246), 10.1007/s00415-024-12808-0)

    Journal of Neurology

  6. Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study

    PLoS ONE, Vol. 20, Núm. 3 March

  7. Dysphagia in Parkinson´s disease. A 5-year follow-up study

    Neurological Sciences, Vol. 46, Núm. 6, pp. 2637-2653

  8. Early Detection of Cancer and Precancerous Lesions in Persons With HIV Through a Comprehensive Cancer Screening Protocol

    Clinical Infectious Diseases, Vol. 80, Núm. 2, pp. 371-380

  9. Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real-world data study

    European Journal of Neurology, Vol. 32, Núm. 1

  10. Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline

    Journal of Neurology, Vol. 272, Núm. 3

  11. Increased mortality and morbidity risk in people with early HIV care interruption in Spain

    AIDS, Vol. 39, Núm. 9, pp. 1224-1234